Drugs / IMF-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01234012 | May 2011 → Nov 2013 | neoplasm | ImmunoFrontier, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01003808 | Nov 2009 → Mar 2012 | esophageal cancer | ImmunoFrontier, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMF-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01234012 ↗ |
| Known as | CHP-NY-ESO-1 | “This study evaluated the safety, immune responses and clinical outcomes of patients who received the CHP-NY-ESO-1 complex vaccine, Drug code: IMF-001.” PMID 24093426 ↗ Oct 2013 |
| Modality | Vaccine | “Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.” PMID 24093426 ↗ Oct 2013 |
| Route | Subcutaneous | “subcutaneously vaccinated with either 100 μg or 200 μg of NY-ESO-1 protein complexed with CHP.” PMID 24093426 ↗ Oct 2013 |